Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: <i>In Vitro</i> and Molecular Docking Studies
Shenouda G. Eliaa, Ahmed A. Al‐Karmalawy, Rasha M. Saleh, Mohamed F. Elshal
Abstract
studies in addition to PCR of pro- and antiapoptotic genes (mTOR, p21, JNK, Bcl2, and MDR1) suggest the chemosensitization effect of EMP combination with DOX which can reduce the required therapeutic dose of DOX in TNBC and eventually will decrease its toxic side effects (especially cardiotoxicity), along with decreasing the chemoresistance of TNBC cells to DOX treatment.
Topics & Concepts
DoxorubicinCardiotoxicityPharmacologyTriple-negative breast cancerApoptosisAnnexinGrowth inhibitionPI3K/AKT/mTOR pathwayIn vitroChemistryCancer researchBiologyBreast cancerMedicineCancerChemotherapyBiochemistryToxicityInternal medicineOrganic chemistryChemotherapy-induced cardiotoxicity and mitigationAdvanced Breast Cancer TherapiesMetabolism, Diabetes, and Cancer